Search

Your search keyword '"T. Filleron"' showing total 22 results
Start Over Author "T. Filleron" Language undetermined
22 results on '"T. Filleron"'

3. Comment effectuer des comparaisons indirectes ajustées par appariement (MAIC) avec imputations multiples des données manquantes et dans un contexte de faibles échantillons ? Une méthodologie illustrée dans le cancer du poumon à partir d'essais cliniques agrégés et de la cohorte nationale ESME-AMLC

Author

C. Esnault, V. Barbet, T. Filleron, G. Chenuc, M. Pérol, D. Debieuvre, N. Girard, X. Quantin, K. Thokagevistk, G. Simon, and L. Baschet

Subjects
Epidemiology, Public Health, Environmental and Occupational Health
Published
2022
Full Text
View/download PDF

10. 250P Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database

Author

C.C. Courtinard, S. Gourgou, W. Jacot, null M. Carton, T. Filleron, D. Couch, B. Asselain, M-C. Le Deley, L. Vacher, A. Antoine, D. Parent, null R. Schiappa, M. Breton, S. Michiels, E.G.C. Brain, O. Guérin, A. Loeb, G. Perrocheau, G. Simon, and C. Bellera

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

12. Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment

Author

J, Attal, B, Cabarrou, T, Valentin, J P, Nesseler, E, Stoeckle, A, Ducassou, T, Filleron, S, Le Guellec, B, Boulet, G, Vogin, G, Ferron, E Cohen-Jonathan, Moyal, M, Delannes, and C, Chevreau

Subjects
Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Extremities, Sarcoma, Chemoradiotherapy, Disease-Free Survival, Neoadjuvant Therapy, Neoplasm Staging, Retrospective Studies
Abstract

Patients with locally advanced grade 2-3 extremity/truncal soft tissue sarcomas (STS) are at high risk of recurrence. The objective of this study was to assess the efficacy and feasibility of neoadjuvant concurrent chemoradiotherapy (cCRT) in selected grade 2-3 patients with limb or trunk wall STS, and to compare this schedule to a sequential approach combining neoadjuvant chemotherapy and adjuvant radiotherapy.We retrospectively included patients who underwent neoadjuvant cCRT at two comprehensive cancer centers from 1992-2016. We then compared these results to those of patients treated with preoperative chemotherapy and postoperative radiotherapy from a third comprehensive cancer center with a propensity score matched analysis.A total of 53 patients were treated by neoadjuvant cCRT; 58 patients could be matched with 29 patients in each treatment group after propensity score matching. Disease-free survival and overall survival at 5 years were 54.9 and 63.5%, respectively with neoadjuvant cCRT, with no significant difference when compared to the sequential treatment group. R0 resection rate was higher (90.9 vs 44.8%, p 0.01) in the cCRT group than in the sequential treatment group during a shorter therapeutic sequence (118 vs 210.5 days, p 0.01), with no impact on the surgical procedure or postoperative complications.cCRT is feasible with acceptable immediate and late toxicities. It could facilitate surgery by increasing the R0 resection rate and improve patient compliance by shortening the therapeutic sequence.

Published
2021

16. Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment

Author

Carine Laurent, Matthieu Carton, A. Martin, V. Desroys du Roure, G. Fajole, Gaëtane Simon, A. Chambon, Agnes Loeb, M. Lebitasy, S. Pallenchier, Y. Belaroussi, T. Filleron, Damien Parent, Lilian Laborde, V. Dejean, T. Habet, Simone Mathoulin-Pélissier, M. Lebouc, H. Faralli, and Sophie Cousin

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, education.field_of_study, Performance status, Epidemiology, business.industry, Proportional hazards model, medicine.medical_treatment, Population, Public Health, Environmental and Occupational Health, Immunotherapy, medicine.disease, medicine.disease_cause, Clinical trial, Internal medicine, Medicine, KRAS, business, Lung cancer, education
Abstract

Introduction Metastatic non-small cell lung cancer is a disease with a poor prognosis and things may improve with the rise of immunotherapy. Clinical trials proved that immunotherapy had better results on survival than chemotherapy as first-line treatment for patients with metastatic lung cancer (MLC). Although clinical trials have strong internal validity, they suffer from restrictive selection criterions and it can be difficult to generalize to real-life patients. We aimed to evaluate if the results of survival when comparing immunotherapy with chemotherapy as first-line therapy for MLC in real-life data are similar to those from clinical trials. Methods All consecutive patients included in the retrospective Epidemio-Strategy Medico Economic (ESME-AMLC– NCT03848052 ) program with a non-small cell MLC treated with a systemic treatment (either chemotherapy alone or immunotherapy alone) between January 2015 and December 2018. Patients diagnosed with a tumor with EGFR, KRAS, ROS or BRAF mutation were excluded. Confounding and indication biases were taken account by analyzing causal relation between treatment allocation and survival by constructing a directed acyclic graph. Progression-free survival was analyzed as secondary outcome. Results ESME database included 21,169 patients and 5,255 individuals were included in the study: 5055 treated with chemotherapy, 200 treated with immunotherapy. Median age at diagnosis was 63 years and male represented 67.7% of the population. Median OS in immunotherapy group was 16.4 months (95% CI = [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95% CI = [11.0–12.2]). In Cox models analyzes, immunotherapy group had better results after 3 months for subjects with performance status (PS) 0–1 (HR = 0.59; 95% CI = [0.42–0.83], P = 0.003) but had poor results before 3 months for subjects with 2, 3 or 4 PS (HR = 2.28; 95% CI = [1.17–4.47], P = 0.016). Conclusion Our results were in favor of benefits on survival of the immunotherapy as first-line treatment for MLC after 3 months for patients in good health condition, as found in clinical trials.

Published
2021
Full Text
View/download PDF

17. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France

Author

M. Pérol, M. Carton, D. Debieuvre, X. Quantin, N. Girard, C. Audigier-Vallette, H. Lena, T. Filleron, R. Schott, R. Gervais, S. Hiret, J. Otto, E. Dansin, P. Dubray Longeras, C. Kaderbhai, A. Madroszyk, C. Clément-Duchêne, E. Pichon, D. Planchard, A. Lemoine, S. Thureau, A. Baranzelli, S. Cousin, S. Schneider, A. Bizieux, J. Le Treut, S. Hominal, C. Dayen, G. Simon, M. Robain, D. Couch, and C. Chouaid

Subjects
Pulmonary and Respiratory Medicine
Published
2021
Full Text
View/download PDF

18. Total body irradiation using Helical Tomotherapy

Author

V, Sarradin, L, Simon, A, Huynh, J, Gilhodes, T, Filleron, and F, Izar

Subjects
Adult, Male, Organs at Risk, Leukemia, Adolescent, Radiotherapy Dosage, Middle Aged, Lymphoma, T-Cell, Cohort Studies, Young Adult, Humans, Female, Radiotherapy, Intensity-Modulated, Organ Sparing Treatments, Whole-Body Irradiation, Retrospective Studies, Stem Cell Transplantation
Abstract

Helical TomoTherapyThe cohort consisted of 11 patients who were treated in our institution between August 2014 and January 2016. The total dose was 12Gy in six fractions in three days. We collected the dose distribution information in the treatment volumes, organs at risk and area of junction. We report retrospectively the clinical events during the first 6 months after the procedure.Median age was 31 years (range, 18-57 years). Median D98% was 11.5Gy (range: 6.6-11.9Gy). The median of the mean doses to the lungs was 8.7Gy (range: 8.5-9.3Gy). The mean dose for the junction area was 12Gy (range: 11.9-12.1Gy). All patients had the total procedure, and all underwent successful engraftment. During the first six months, nine patients had at least one grade 3 or 4 toxicity that was due essentially to graft versus host disease. No patient had radiation pneumonitis. The toxicities were both more frequent and of higher grade during the first three months.Total body irradiation using helical TomoTherapy

Published
2017

19. MEDICAL RADIATION THERAPIES

Author

I. Ahmed, A. Biswas, S. Krishnamurthy, P. Julka, G. Rath, M. Back, D. Huang, C. Gzell, J. Chen, M. Kastelan, P. Gaur, H. Wheeler, S. N. Badiyan, C. G. Robinson, J. R. Simpson, D. D. Tran, K. M. Rich, J. L. Dowling, M. R. Chicoine, E. C. Leuthardt, A. H. Kim, J. Huang, S. R. Michaelsen, I. J. Christensen, K. Grunnet, M.-T. Stockhausen, H. Broholm, M. Kosteljanetz, H. S. Poulsen, M. Tieu, E. Lovblom, M. Macnamara, W. Mason, D. Rodin, E. Tai, K. Ubhi, N. Laperriere, B.-A. Millar, C. Menard, B. Perkins, C. Chung, J. Clarke, A. Molinaro, J. Phillips, N. Butowski, S. Chang, A. Perry, J. Costello, A. DeSilva, J. Rabbitt, M. Prados, A. L. Cohen, C. Anker, D. Shrieve, B. Hall, K. Salzman, R. Jensen, H. Colman, O. Farber, U. Weinberg, Y. Palti, B. Fisher, H. Chen, D. Macdonald, G. Lesser, S. Coons, D. Brachman, S. Ryu, M. Werner-Wasik, J.-P. Bahary, A. Chakravarti, M. Mehta, T. Gupta, V. Nair, S. Epari, J. Godasastri, A. Moiyadi, P. Shetty, S. Juvekar, R. Jalali, U. Herrlinger, N. Schafer, J. Steinbach, A. Weyerbrock, P. Hau, R. Goldbrunner, R. Kohnen, H. Urbach, W. Stummer, M. Glas, C. Houillier, H. Ghesquieres, C. Chabrot, C. Soussain, G. Ahle, S. Choquet, P. Faurie, J.-O. Bay, J. Vargaftig, C. Gaultier, E. Nicolas-Virelizier, K. Hoang-Xuan, O. Iskanderani, F. Izar, A. Benouaich-Amiel, T. Filleron, E. Moyal, C. Iweha, S. Jain, E. Melian, A. Sethi, K. Albain, D. Shafer, B. Emami, X.-T. Kong, S. Green, E. Filka, R. Green, W. Yong, P. Nghiemphu, T. Cloughesy, A. Lai, S. Mallick, S. Roy, S. Purkait, S. Gupta, P. K. Julka, G. K. Rath, C. Marosi, J. Thaler, C. Ay, A. Kaider, E.-M. Reitter, J. Haselbock, M. Preusser, B. Flechl, C. Zielinski, I. Pabinger, S.-I. Miyatake, M. Furuse, T. Miyata, E. Yoritsune, S. Kawabata, T. Kuroiwa, Y. Muragaki, T. Maruyama, H. Iseki, J. Akimoto, S. Ikuta, M. Nitta, K. Maebayashi, T. Saito, Y. Okada, S. Kaneko, A. Matsumura, K. Karasawa, Y. Nakazato, T. Kayama, L. B. Nabors, K. L. Fink, T. Mikkelsen, D. Grujicic, R. Tarnawski, D.-H. Nam, M. Mazurkiewicz, M. Salacz, L. Ashby, L. Thurzo, V. Zagonel, R. Depenni, J. R. Perry, J. Henslee-Downey, M. Picard, D. A. Reardon, N. Nambudiri, L. Nayak, D. LaFrankie, P. Wen, D. Ney, J. Carlson, D. Damek, P. Blatchford, L. Gaspar, B. Kavanagh, A. Waziri, K. Lillehei, K. Reddy, C. Chen, I. Rashed, K. Barton, D. Anderson, V. Prabhu, R. Rusch, M. Belongia, M. Maheshwari, S. Firat, D. Schiff, A. Desjardins, M. Glantz, M. Chamberlain, W. Shapiro, S. Gopal, K. Judy, S. Patel, A. Mahapatra, J. Shan, D. Gupta, K. Shih, J. A. Bacha, D. Brown, W. J. Garner, A. Steino, R. Schwart, S. Kanekal, M. Li, L. Lopez, H. A. Burris, C. Soderberg-Naucler, A. Rahbar, G. Stragliotto, A. J. Song, A. M. S. Kumar, E. S. Murphy, T. Tekautz, J. H. Suh, V. Recinos, S. T. Chao, J. Spoor, K. Korami, J. Kloezeman, R. Balvers, C. Dirven, M. Lamfers, S. Leenstra, A. Sumrall, D. Haggstrom, A. Crimaldi, J. Symanowski, P. Giglio, A. Asher, S. Burri, G. Sunkersett, Z. Khatib, C. M. Prajapati, E. E. Magalona, M. Mariano, I. M. Sih, R. Torcuator, W. Taal, H. Oosterkamp, A. Walenkamp, L. Beerenpoot, M. Hanse, J. Buter, A. Honkoop, D. Boerman, F. de Vos, R. Jansen, F. van der Berkmortel, D. Brandsma, R. Enting, J. Kros, J. Bromberg, I. van Heuvel, M. Smits, R. van der Holt, R. Vernhout, M. van den Bent, W. Wick, C. Suarez, J. Rodon, P. Forsyth, I. Gueorguieva, A. Cleverly, T. Burkholder, D. Desaiah, M. Lahn, L. Zach, D. Guez, D. Last, D. Daniels, O. Nissim, Y. Grober, C. Hoffmann, D. Nass, A. Talianski, R. Spiegelmann, Z. Cohen, and Y. Mardor

Subjects
Abstracts, Cancer Research, medicine.medical_specialty, Text mining, Oncology, business.industry, Medicine, Medical physics, Neurology (clinical), business, Medical radiation
Published
2013
Full Text
View/download PDF

20. Résections rectosigmoïdiennes cœlioscopiques pour endométriose digestive : résultats chirurgicaux et fonctionnels

Author

T. Filleron, Laurent Boileau, R. de Tayrac, S. Laporte, J.-P. Rouanet, Pierre Marès, and J F Bourgaux

Subjects
Gynecology, medicine.medical_specialty, business.industry, Pelvic pain, Treatment outcome, MEDLINE, Obstetrics and Gynecology, Retrospective cohort study, General Medicine, Reproductive Medicine, Quality of life, Colon surgery, medicine, Endometriosis surgery, Dysuria, medicine.symptom, business
Abstract

Journal de Gynecologie Obstetrique et Biologie de la Reproduction - Vol. 41 - N° 2 - p. 128-135

Published
2012
Full Text
View/download PDF

22. Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?

Author

G. Ferron, R. Aziza, M. Delannes, T. Filleron, B. Marquès, D. Labarre, and C. Chevreau

Subjects
Cancer Research, medicine.medical_specialty, Oncology, medicine.diagnostic_test, business.industry, medicine, Soft tissue, Magnetic resonance imaging, Radiology, business, Resection
Abstract

10582 Background: The role of systematic magnetic resonance imaging (MRI) surveillance after resection of soft-tissue sarcomas (STS) of the limb is opened to debate. The aim of our study was to retrospectively evaluate the effectiveness of a MRI surveillance schedule performed in adult patients. Methods: 124 adult patients have been treated from 1996 to 2006 for a non-metastatic limb STS at our centre: 86 patients (70%) had clear resection margins (R0) and 111 patients (90%) received an adjuvant radiotherapy. 663 MRI examinations were performed, with a median of 5 per patient [range: 1 to 5]. The rythm of surveillance schedule was respected in 57% of the examinations. Results: Forty-one patients (33%) prematurely withdrew from the planned radiological surveillance due to metastasis diagnosis (15 cases), 5-year remission duration (5 cases), other reasons (12 cases), and drop out (9 cases). Among the 11 local recurrences (9%) which were observed, MRI was able to detect only 2 asymptomatic local recurrences, 1 with and 1 without synchronous metastasis, both had microscopically involved margins (R1). In contrast, MRI showed 11 false-positive cases. As the predictive positive value of MRI was 42%, clinical surveillance seems to be more effective. The evaluation of the cost of the systematic MRI surveillance is 200,000 euros. Clinical examination failed in 2 cases (2 asymptomatic local recurrences detected by MRI) as did MRI surveillance (2 false negative cases). In our study, cost-effectiveness was better with clinical examination than MRI surveillance. Conclusions: As observed in our study, systematic MRI surveillance is not relevant for the follow-up of all limb soft-tissue sarcomas. A prospective study could be promoted to evaluate the MRI surveillance of patient at high risk of local recurrence. No significant financial relationships to disclose.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results